Richard Lafayette, MD, FACP, Stanford University Medical Center, explains the significance of this second approval in a month ...

Amid all the volatility, some companies are proving resilient by performing much better than the market. Some of these look ...

Novartis has terminated a phase 2 trial evaluating an investigational ADAMTS-5 inhibitor for patients with osteoarthritis knee pain. The Big Pharma company discontinued the study testing intra ...

Su principio activo, atrasentan, ha sido desarrollado por la compañía estadounidense Chinook Therapeutics adquirida por Novartis en 2023 por 3.200 millones de dólares. 'Vanrafia' está indicado ...

As targeted treatments such as Tarpeyo (Calliditas), Filspari (Travere), Fabhalta (Novartis), and most recently Vanrafia (Novartis) enter the market, this research captures how patients are navigating ...

Fabhalta, a therapy for a rare blood disease, earned the green light in 2023, while Vanrafia, a medicine for a kidney disease, did so just this month. Novartis' deep pipeline will lead to more ...